ConductScience.org, home

Comparison · NCT00699153-b7fb48b1

Loteprednol Etabonate vs Vehicle: Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Loteprednol Etabonate vs Vehicle: Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0. Trial comparisons, record NCT00699153-b7fb48b1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00699153-b7fb48b1

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3150.2550.382wilson
Risk in group 20.1140.07710.165wilson
Risk difference, group 1 minus group 20.2010.1230.278newcombe hybrid score
Risk ratio, group 1 over group 22.771.794.28log
Odds ratio, group 1 over group 23.582.126.06log
Number needed to treat, for one more participant with the outcome on Loteprednol Etabonate than on Vehicle4.973.68.16from the risk difference interval

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Loteprednol EtabonateLoteprednol Etabonate Ophthalmic Ointment 0.5%64203OG000
Group 2VehicleVehicle of Ophthalmic Loteprednol Etabonate23202OG001

Outcome

Type
PRIMARY
Title
Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0
Description
A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.
Time frame
Postoperative day 8 (Visit 5)
Population
Intent to treat population, subjects who had missing data or took rescue medication prior to visit 5 were imputed as no.

Source ClinicalTrials.gov

Trial

Title
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
NCT number
NCT00699153
Phases
PHASE3
Conditions
Ocular Inflammation
Interventions
Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate
Lead sponsor
Bausch & Lomb Incorporated
Results first posted
2010-09-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00699153-b7fb48b1